Compare Enveric Biosciences Inc (ENVB) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs VNET Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: VNET Group Inc is far larger — about 216.2× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 4,955,295). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and VNET Group Inc for 16 Days on average.
| ENVB | VNET | |
|---|---|---|
Market Cap | $6.80M | $1.47B |
Volume | 64,867 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $10.80 | $14.03 |
52-Week Low | $1.27 | $5.13 |
Typical Hold Time | 14 Days | 16 Days |
Enterprise Value | -$1.49M | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
VNET trades at $5.42, up 0.56% today but near a 52-week low. Technicals are bearish with moving averages signaling sell, while fundamentals show revenue growth to $9.95B in 2025 but net losses of $256.77M. Recent news includes a strategic investment closing and a new low, reflecting mixed sentiment amid high institutional interest and negative cash flow trends.
Outlook: Strategic partnerships and AI demand offer growth, but high debt, negative margins, and bearish technicals pose significant risks. Analyst consensus is moderately bullish (62.5% buy), yet profitability challenges and leverage require caution for investors seeking turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
